Thursday, May 15, 2025
8:00 am Light Breakfast & Morning Networking
8:55 am Chair’s Opening Remarks
Targeting Unmet Areas for Transformative Therapies & Reversal of Disease Progression
9:00 am Refining Patient Stratification & Tailoring Pediatric Therapies to Transform IBD Care
Synopsis
- Exploring age-specific markers for optimized pediatric IBD management
- Advancing therapeutic approaches to address pediatric-specific challenges in IBD
- Developing stratification protocols for personalized treatments in pediatric patients
9:30 am Panel Discussion: Enhancing Precision Medicine & Optimizing Stratification to Deliver Effective Fibrosis Therapies
Synopsis
- Refining stratification approaches to identify high-risk patients for fibrosis
- Tailoring therapies based on molecular and genetic fibrosis profiles
- Can biopharma harness stratification tools to improve therapy outcomes and efficiency?
10:00 am Morning Networking Break
Supercharging IBD Treatment with Novel Therapeutic Pathways to Deliver Superior & Transformative Patient Care
11:00 am Harnessing PD-1 Agonists for Novel Therapeutic Approaches in Autoimmune Diseases
Synopsis
- Exploring the novel mechanism of PD-1 agonists in T-cell modulation to treat autoimmune diseases
- Leveraging biomarker data to refine patient selection and optimize therapeutic outcomes
- Integrating translational research insights into clinical strategy for ulcerative colitis and other inflammatory conditions (RA)
11:30 am Development of a Novel Immune Checkpoint Enhancer as a Potential Therapeutic Medicine for Ulcerative Colitis
Synopsis
- An in-depth exploration for the capacity of emerging approaches regarding non-immune cells to revolutionize our understanding of IBD
- Exploring the capacity for precision medicine strategies target these unconventional players to open new avenues for IBD treatment innovation
12:00 pm Targeting CCR9: Advancing Precision Therapies for Inflammatory Bowel Disease
Synopsis
- Leveraging CCR9 inhibition to improve therapeutic targeting and address IBD heterogeneitys
- Exploring clinical outcomes and patient stratification strategies for CCR9-targeted therapies
- Innovating treatment pathways to optimize safety and efficacy in precision medicine for IBD
12:30 pm Lunch Break & Networking
Deciphering Novel Targets & Preclinical Models to Accelerate Precision IBD Therapies & Enhance Clinical Success
1:30 pm Deciphering GPR35: A Novel Target for Epithelial-Driven Therapeutics in IBD
Synopsis
- Unravelling the role of GPR35 in epithelial biology to address inflammatory bowel disease progression
- Investigating the therapeutic potential of GPR35 antagonists in preclinical models and patient-derived systems
- Exploring the use of biomarkers to stratify patients for targeted therapeutic interventions and enhanced clinical outcomes
2:00 pm Inflammatory Resolution of Ulcerative Colitis – The Melanocortin System
Synopsis
- Melanocortin agonists don’t block they immune system, they promote resolution of inflammation
- Animal studies demonstrate the effectiveness and mechanisms of action of these agonists
- A Phase 2 clinical study showed 33% remission vs 0% placebo and 78% clinical response vs 33% placebo
2:30 pm Roundtable Discussion: Advancing Autoimmune Therapeutics: Precision Approaches to Inflammation
Synopsis
- Which emerging targets do you see as most promising for transforming the treatment of autoimmune and inflammatory diseases
- What are the key hurdles to validating novel targets, clinically?
- Where do you see the most opportunity to combine precision medicine tools (e.g. multi-omics, digital pathology, AI) with new target exploration to drive better outcomes in autoimmune disease?
3:00 pm Deciphering the Optimal Preclinical Models for Streamlined Stratification for More Efficacious Clinical Trials
Synopsis
- How to identify preclinical models that accurately mimic patient heterogeneity and disease complexity
- Evaluating the predictive power of preclinical models for improving molecular diagnostic evaluation of patients
- How can one refine models to reduce clinical trial failure rates and improve translational outcomes